Barclays
SNTI icon

Barclays’s Senti Biosciences Holdings SNTI Stock Holding History

Barclays’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845 Buy
+768
New +$751 ﹤0.01% 4944
2025
Q3 		– Sell
-569
Closed -$1.2K – 5711
2025
Q2 		$1.2K Buy
569
+539
+1,797% +$1.71K ﹤0.01% 5055
2025
Q1 		$101 Hold
30
– – ﹤0.01% 5128
2024
Q4 		$105 Sell
30
-470
-94% -$1.5K ﹤0.01% 5182
2024
Q3 		$1.13K Buy
+500
New +$1.32K ﹤0.01% 5118

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $357M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Barclays's SNTI Position: Q2 2026 in Review

Barclays opened a new position in Senti Biosciences Holdings (SNTI) in Q2 2026: 768 shares worth $845. The stake represents ﹤0.01% of the portfolio and ranks #4944 among its holdings. This is a return to the name: Barclays previously reported a position in SNTI as recently as Q2 2025.

Barclays first reported a position in SNTI in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.2K in Q2 2025. 19 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

  • Barclays held 768 shares of Senti Biosciences Holdings worth $845 as of Q2 2026.
  • Senti Biosciences Holdings was a new Barclays position in Q2 2026.
  • Senti Biosciences Holdings made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4944 holding.
  • Barclays first reported a position in Senti Biosciences Holdings in Q3 2024 and has held it in 5 quarters since.
  • Barclays's Senti Biosciences Holdings position peaked at $1.2K in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.